Unlocking the true potential of Image Guided Ablation Therapy
Real time Predictive visualization of true ablation damage
Real-time ablation. Visualized.
The world’s first and only image analysis system that predicts and visualizes the 24-hour post-treatment ablation morphology in real-time
Allowing physicians to see where they have previously been blind
BioTrace™ interfaces with commercial ultrasound imaging systems to track the tissue’s unique “biological signature” when responding to heat during thermal ablation. This signature is used to predict and visualize the post 24-hour thermal effect in real-time, optimizing the surgeon’s level of control and accuracy during the procedure, to minimize healthy tissue damage and maximize target tissue ablation.
Providing vision. Optimizing results.
A must have system for optimal ablation
Reduced recurrence rates
Maximize efficacy and minimize leftover pathologies
Increased safety
Prevent severe injuries due to overtreatment
Cost effective
No hardware necessary
Quick & easy to adopt
No change to existing surgical procedures
Case Studies
One real-time image is better than a thousand simulations
-
CASE 01
- 61 Year-Old Patient
- RFA Ablation
- Tumor Size 1.8 cm
- Liver Segment #3
- Ablation time: 3 min
92%
BioTrace™ accuracy
compared with 24h post CECT
92%
BioTrace™ accuracy
compared with 24h post CECT
-
CASE 02
- 58 Year-old Patient
- RFA Ablation
- Tumor Size 2.2 cm
- Liver Segment #6
- Ablation time: 2.4min
91% BioTrace™ accuracy
compared with 24h post CECT
91% BioTrace™ accuracy
compared with 24h post CECT
-
CASE 03
- 63 Year-old Patient
- MW Ablation
- Tumor Size 1.5 cm
- Liver segment #4
- Ablation time: 2min
90% BioTrace™ accuracy
compared with 24h post CECT
90% BioTrace™ accuracy
compared with 24h post CECT
Transforming ablation treatments into guided precision therapies
Current Application
Oncology Liver tumor ablation
Advancing thermal ablation into the first line treatment option for tumor removal
Pipeline
Cardiovascular
Transitioning from complicated guess-work into precise, real-time feedback dependent treatments
Pain management
Dramatically increase safety in high-risk nerve-ablation procedures
Team
Head of N. America
Board of Directors
Chairman of the Board
MR. ARIE ROSENFELD
Former President & CEO, Scitex Corp
Director
MR. YOSSI ABU
Founder & CEO, TechsoMed
Director
MR. EIJI KAKIUICHI
Chairman, SCREEN Holdings
Director
MR. TODD KALOUDIS
Managing Director, Cobro Ventures
Director
MR. FRED SHANE
Managing Partner, Axil Capital
Director
MR. WANG CHONG
Executive Director, Yonghua Capital
Partnerships
Investors
Partners
Clinical
News
December 2022
TechsoMed announces the opening of a new subsidiary in Bremen with Fraunhofer Mevis to accelerate End-to-End solutions for Image-Guided Thermal Ablation therapy
October 2022
TechsoMed announces completion of full enrollment in pivotal US trial, evaluating its BioTraceIO software for liver ablation outcomes assessment in liver cancer patients
Contact info
TechsoMed
Tel: +972-8-6198866
Email: info@techsomed.com
Meir Weisgal 2, Rehovot, Israel
© 2023 Techsomed All Rights Reserved | Website by Pearlcom.co.il
Read our Privacy Policy
© 2021 Techsomed All Rights Reserved
Website by Pearlcom.co.il
The BioTrace IO solution is not approved for sale or distribution in the US and is limited by U.S. law to investigational use